# Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma

> **NCT06468605** · PHASE1 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Recurrent or Progressive High-grade Glioma

## Interventions

- **BIOLOGICAL:** JCXH-211

## Key facts

- **NCT ID:** NCT06468605
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-11-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Immorna, the funder withdrew the funds to run this study
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468605, "Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06468605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*